Head-to-head evidence
FF-10832 vs Gemcitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ribonucleotide reductase / DNA polymerase (dCTP competition) · full Non-Small Cell Lung Cancer pipeline
FF-10832
Developed by Fujifilm Pharmaceuticals U.S.A., Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2029 · NCT05318573 (registry estimate)
Gemcitabine
Marketed by Eli Lilly
NCT00003589 · Phase 3 · completed
This Phase 3 trial randomly assigned 450 people with advanced lung cancer to one of three chemotherapy combinations: paclitaxel with cisplatin, gemcitabine with cisplatin, or paclitaxel with gemcitabine. The registry does not say whether or how treatment assignment was masked. Median overall survival was 8.9 months on gemcitabine with cisplatin, 8.1 months on paclitaxel with cisplatin and 6.7 months on paclitaxel with gemcitabine, with response rates of 36.6%, 31.8% and 27.7%. The published report gives these figures without a statistical comparison between the arms, so no combination can be called the winner on this evidence.
Next expected readout: October 2026 · NCT06447662 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FF-10832's landscape · Gemcitabine's landscape